SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2023 to Q3 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
SABS on Nasdaq
Shares outstanding
47,559,740
Price per share
$3.77
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
28,023,938
Total reported value
$56,328,113
% of total 13F portfolios
0%
Share change
+26,100,064
Value change
+$52,469,483
Number of holders
34
Price from insider filings
$3.77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 10% $54,973,720 25,931,000 Vivo Opportunity Fund Holdings, L.P. 29 Sep 2025
Woodline Partners LP 9.9% $14,293,092 7,125,881 Woodline Partners LP 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 10% $10,365,208 5,167,618 BVF PARTNERS L P/IL 30 Sep 2025
Commodore Capital LP 9.9% $9,588,711 4,522,977 Commodore Capital LP 26 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $9,331,180 4,401,500 RA Capital Management, L.P. 26 Sep 2025
PERCEPTIVE ADVISORS LLC 7.3% $13,088,916 3,471,861 Perceptive Advisors LLC 14 Jan 2026
RTW INVESTMENTS, LP 10% $1,311,149 1,024,335 RTW Investments, LP 31 Dec 2024

As of 30 Sep 2025, 34 institutional investors reported holding 28,023,938 shares of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS). This represents 59% of the company’s total 47,559,740 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Vivo Capital, LLC 24% 11,420,000 1.8% $22,954,200
RA CAPITAL MANAGEMENT, L.P. 9.3% 4,401,500 0.11% $8,847,015
Commodore Capital LP 9.3% 4,401,500 0.43% $8,847,015
Woodline Partners LP 6% 2,850,881 0.03% $5,730,271
Sessa Capital IM, L.P. 4.6% 2,198,457 +380% 0.11% $4,418,899
BVF INC/IL 2% 932,697 +1.6% 0.08% $1,874,721
SPHERA FUNDS MANAGEMENT LTD. 1.2% 566,395 0.27% $1,138,454
VANGUARD GROUP INC 0.77% 365,753 +30% 0% $735,163
HB Wealth Management, LLC 0.65% 307,500 0% $618,075
AWM Investment Company, Inc. 0.42% 200,000 0.04% $402,000
GEODE CAPITAL MANAGEMENT, LLC 0.18% 85,718 +1.1% 0% $172,317
RENAISSANCE TECHNOLOGIES LLC 0.17% 80,840 +633% 0% $162,488
Pathstone Holdings, LLC 0.11% 50,650 0% 0% $101,807
Virtu Financial LLC 0.04% 19,982 0% $40,000
Kovitz Investment Group Partners, LLC 0.04% 19,201 0% 0% $38,594
First PREMIER Bank 0.04% 18,986 0% 0.01% $38,000
DIMENSIONAL FUND ADVISORS LP 0.03% 15,781 0% $31,720
ADAR1 Capital Management, LLC 0.03% 15,000 0% $30,150
UBS Group AG 0.03% 13,221 +24% 0% $26,574
Kestra Advisory Services, LLC 0.03% 11,930 0% 0% $23,979
NORTHERN TRUST CORP 0.02% 11,387 0% 0% $22,888
GOLDMAN SACHS GROUP INC 0.02% 11,221 0% $22,554
CAXTON CORP 0.02% 10,935 0.1% $21,979
BlackRock, Inc. 0.01% 6,339 -9.5% 0% $12,741
OSAIC HOLDINGS, INC. 0.01% 4,824 -2.3% 0% $9,994

Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 28,023,938 $56,328,113 +$52,469,483 $2.01 34
2025 Q2 1,923,874 $3,369,565 -$378,633 $1.76 25
2025 Q1 2,209,552 $2,994,479 -$1,776,863 $1.36 26
2024 Q4 2,628,252 $10,098,558 -$1,284,579 $3.80 25
2024 Q3 3,141,736 $8,482,377 +$68,507 $2.70 24
2024 Q2 3,127,151 $9,694,108 -$923,500 $3.10 21
2024 Q1 3,339,666 $15,162,138 -$15,608,797 $4.54 23
2023 Q4 8,791,109 $6,055,351 +$6,055,351 $0.69 3